Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 12/2014

01-11-2014 | Hepatobiliary Tumors

Survival Advantage of Radiofrequency Ablation Over Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma and Good Performance Status Within the Milan Criteria

Authors: Po-Hong Liu, MD, Yun-Hsuan Lee, MD, Chia-Yang Hsu, MD, MPH, Yi-Hsiang Huang, MD, PhD, Yi-You Chiou, MD, Han-Chieh Lin, MD, Teh-Ia Huo, MD

Published in: Annals of Surgical Oncology | Issue 12/2014

Login to get access

Abstract

Background

Performance status is closely linked with survival in patients with hepatocellular carcinoma (HCC). We evaluated the impact of performance status on patients with small HCC receiving radiofrequency ablation (RFA) versus transarterial chemoembolization (TACE).

Methods

A total of 424 and 282 patients within the Milan criteria undergoing RFA and TACE, respectively, were analyzed. Patients were classified as performance status 0 (n = 516) and performance status ≥1 (n = 190) groups. A propensity-score matching analysis with preset caliper width was used. A total of 167 and 68 matched pairs were selected from patients with a performance status of 0 and ≥1, respectively.

Results

Radiofrequency ablation provided significantly better long-term survival than TACE for patients within the Milan criteria (p < 0.01). After being stratified by performance status and matched in the propensity model, the baseline characteristics were similar between the RFA and TACE groups for patients with a performance status of 0 or ≥1. RFA provided significantly better long-term survival than TACE in patients with a performance status of 0 in the propensity model (p < 0.05); TACE was significantly associated with 1.784-fold increased risk of mortality (95 % confidence interval 1.075–2.506) by using the Cox proportional hazards model. TACE was not a significant prognostic predictor in patients with a performance status ≥1 in the propensity model.

Conclusions

For HCC patients within the Milan criteria with a performance status of 0, RFA provides better long-term survival than TACE. RFA should be considered a priority treatment in inoperable HCC patients within the Milan criteria. Performance status is a feasible surrogate marker to enhance treatment allocation.
Literature
1.
GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide. IARC Cancer Base No. 10. Lyon; International Agency for Research on Cancer. 2010. http://​globocan.​iarc.​fr. Accessed 1 May 2013.
2.
Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.PubMedCrossRefPubMedCentral
3.
de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol. 2012;56 Suppl 1:S75–87.PubMedCrossRef
4.
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.PubMedCrossRef
5.
Hsu CY, Hsia CY, Huang YH, et al. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer. 2010;116:3006–14.PubMedCrossRef
6.
Fontana RJ, Hamidullah H, Nghiem H, et al. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transplant. 2002;8:1165–74.PubMedCrossRef
7.
Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.PubMedCrossRef
8.
Wong RJ, Devaki P, Nguyen L, Cheung R, Nguyen MH. Ethnic disparities and liver transplantation rates in hepatocellular carcinoma patients in the recent era: results from the Surveillance, Epidemiology, and End Results registry. Liver Transplant. 2014;20:528–35.CrossRef
9.
Bargellini I, Sacco R, Bozzi E, et al. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. Eur J Radiol. 2012;81:1173–8.PubMedCrossRef
10.
Hsu KF, Chu CH, Chan DC, et al. Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function. Eur J Radiol. 2012;81:466–71.PubMedCrossRef
11.
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.PubMedCrossRef
12.
Varela M, Sala M, Llovet JM, Bruix J. Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2003;17 Suppl 2:98–102.PubMedCrossRef
13.
Hsu CY, Lee YH, Hsia CY, et al. Performance status enhances the selection of treatment for patients with hepatocellular carcinoma within the milan criteria. Ann Surg Oncol. 2013;20:2035–42.PubMedCrossRef
14.
Hsu CY, Lee YH, Hsia CY, et al. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology. 2013;57:112–9.PubMedCrossRef
15.
European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.
16.
Grant BF, Dufour MC, Harford TC. Epidemiology of alcoholic liver disease. Semin Liver Dis. 1988;8:12–25.PubMedCrossRef
17.
Hsu CY, Huang YH, Hsia CY, et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol. 2010;53:108–17.PubMedCrossRef
18.
Llovet JM, Fuster J, Bruix J, Barcelona-Clinic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transplant. 2004;10:S115–20.CrossRef
19.
Lee YH, Hsu CY, Huang YH, et al. Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Gastroenterol Hepatol. 2012;27:1581–8.PubMedCrossRef
20.
Pearl J. Understanding propensity scores. In: Pearl J, editor. Causality: models, reasoning, and inference. 2nd ed. Cambridge: Cambridge University Press; 2009:348–51.CrossRef
21.
D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–81.PubMedCrossRef
22.
Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10:150–61.PubMedCrossRefPubMedCentral
23.
Lo CM. Deceased donation in Asia: challenges and opportunities. Liver Transplant. 2012;18 Suppl 2:S5–7.CrossRef
24.
Yin XY, Xie XY, Lu MD, et al. Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors. Cancer. 2009;115:1914–23.PubMedCrossRef
25.
Kong WT, Zhang WW, Qiu YD, et al. Major complications after radiofrequency ablation for liver tumors: analysis of 255 patients. World J Gastroenterol. 2009;15:2651–6.PubMedCrossRefPubMedCentral
26.
27.
28.
Hsu CY, Huang YH, Chiou YY, et al. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver Transplant. 2011;17:556–66.CrossRef
29.
Hiraoka A, Michitaka K, Horiike N, et al. Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients. J Gastroenterol Hepatol. 2010;25:403–7.PubMedCrossRef
30.
Pinter M, Hucke F, Graziadei I, et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology. 2012;263:590–9.PubMedCrossRef
31.
Kalva SP, Pectasides M, Liu R, et al. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2014;37:381–7.PubMedCrossRef
Metadata
Title
Survival Advantage of Radiofrequency Ablation Over Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma and Good Performance Status Within the Milan Criteria
Authors
Po-Hong Liu, MD
Yun-Hsuan Lee, MD
Chia-Yang Hsu, MD, MPH
Yi-Hsiang Huang, MD, PhD
Yi-You Chiou, MD
Han-Chieh Lin, MD
Teh-Ia Huo, MD
Publication date
01-11-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 12/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3831-2

Other articles of this Issue 12/2014

Annals of Surgical Oncology 12/2014 Go to the issue

Gynecologic Oncology

Influence of Intraperitoneal Dissemination Assessed by Laparoscopy on Prognosis of Advanced Ovarian Cancer: An Exploratory Analysis of a Single-Institution Experience

Endocrine Tumors

Predictors of Hemodynamic Instability During Surgery for Pheochromocytoma

Healthcare Policy and Outcomes

Society of Surgical Oncology 2014 Presidential Address

Colorectal Cancer

Treatment Delay in Surgically-Treated Colon Cancer: Does It Affect Outcomes?

Pancreatic Tumors

Long-term Survival After Pancreatic Resection for Renal Cell Carcinoma Metastasis

Colorectal Cancer

A Safety and Feasibility Study of an Allogeneic Colon Cancer Cell Vaccine Administered with a Granulocyte–Macrophage Colony Stimulating Factor–Producing Bystander Cell Line in Patients with Metastatic Colorectal Cancer